皮下使用的拉克萨米德治疗发作.
Natalie McCarthy1, Elizabeth Freshwater2, Nial McCarron1
1Medical, Myton Hospices, Warwick, UK.
BMJ supportive & palliative care
|February 21, 2024
概括
管理生命末期的发作对于舒适至关重要. 本案例研究探讨了使用皮下lacosamide,作为标准二胺的替代品,以有效地防止其他治疗失败时的活动.
科学领域:
- 抚慰性护理是一种缓解性护理.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 生命末期的发作管理对于患者的舒适性和护理人员的福祉至关重要.
- 高剂量的皮下二是标准治疗方法,但在有效性方面存在局限性.
- 耐火性发作在息护理环境中构成了重大挑战.
研究的目的:
- 调查皮肤下注拉科萨米德作为替代抗治疗的疗效.
- 介绍一个案例,证明了lacosamide在治疗生命末期耐火性发作的成功使用.
- 突出对生命末期发作患者的潜在治疗选择,这些患者对标准疗法没有反应.
主要方法:
- 一个病例报告详细介绍了皮下施用lacosamide的情况.
- 监测发作活动和患者对干预的反应.
- 审查关于生命末期发作管理的现有文献.
主要成果:
- 皮下注射lacosamide成功地预防了发作活动.
- 患者经历了发作频率的减少和舒适度的提高.
- 当二胺药物不足时,二胺提供了一个有效的替代品.
结论:
- 皮下注射的lacosamide可以是一个可行的和有效的选择来管理生命结束时的发作.
- 这种方法可以提高患者的舒适度,并减少息治疗中的痛苦.
- 对皮下抗药的进一步研究是有必要的.
相关概念视频
Antiepileptic Drugs: Sodium Channel Blockers
559
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
559
Antiepileptic Drugs: Potassium Channel Activators
183
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
183
Local Anesthetics: Clinical Application as Spinal Anesthesia
629
Spinal anesthetics are given during lower abdomen and limb surgeries to block sensory and motor neurons. They are administered in the mid to low lumbar regions, primarily acting on the cauda equina's nerve roots. The blockade level depends on the local anesthetic (LA) concentration. Usually, low LA concentrations are sufficient to block sensory fibers, while only high LA concentrations block motor fibers. Other factors like injection volume and speed, the patient's posture, and the drug...
629
Local Anesthetics: Clinical Application as Surface, Infiltration, and Conduction Block Anesthesia
1.1K
Depending on the target organ, local anesthetics (LAs) can be administered via various routes. In surface anesthesia, LAs are applied directly to the surface of the skin or mucous membranes. It is widely used for topical skin numbing before venipuncture or minor surgical procedures. Commonly used surface local anesthetics are lidocaine or benzocaine sprays or creams. Surface anesthesia occurs within 5 minutes and lasts for about 60 minutes. One of the main disadvantages of topical anesthesia is...
1.1K
Antiepileptic Drugs: Glutamate Antagonists
355
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
355
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
301
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
301


